Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIL_FOLL19: Shortened vs Standard Immunochemotherapy in High Tumor Burden Follicular Lymphoma
NCT05058404Phase 3Active, not recruiting
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Dec 2021
- Primary completion
- Jul 2028
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab, obinutuzumab, bendamustine, cyclophosphamide, doxorubicin in follicular lymphoma (FL), sponsored by Fondazione Italiana Linfomi. Started Dec 2021; status: active, not recruiting.
02
Drugs
rituximabobinutuzumabbendamustinecyclophosphamidedoxorubicin
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05058404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05058404.